SCHEMBL4739173

SCHEMBL4739173

O=c1cc(O)nc(-c2c(Br)cccc2Br)n1Cc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
LMNA P02545 5/20 0.41
MAPT P10636 4/20 0.41
TSHR P16473 2/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 3/20 0.40
CYP2C19 P33261 3/20 0.40
USP2 O75604 2/20 0.40
CYP2D6 P10635 2/20 0.40
CCR2 P41597 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
CARM1 Q86X55 1/20 0.38
CYP3A4 P08684 2/20 0.38
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4739137 0.90 ALDH1A1 (0.52) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4738470 0.84 LMNA (0.51) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4739135 0.83 ALDH1A1 (0.52) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4784822 0.79 MEN1 (0.45) ALDH1A1MEN1KMT2AMAPTCCR2
SCHEMBL4739942 0.79 ALDH1A1 (0.45) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4741832 0.77 CCR9 (0.44) MEN1KMT2ASMN1; SMN2POLBRAB9A
SCHEMBL4741826 0.75 CCR2 (0.43) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4992689 0.73 EGLN3 (0.63) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4737515 0.73 CASR (0.45) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL4740165 0.71 KDM4E (0.48) ALDH1A1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 ALDH1A1 513/4885MEN1 2935/4885KMT2A 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.